Our method of selection is one of our greatest assets. A carefully designed program, we begin with resources and research projects from leading translational R & D centers. We only consider projects with a significant history of peer-reviewed literature in addition to large scale grant support. Moreover, we ensure aspects of early stage funding such as intellectual property protection, patent options and market competition are completed. As such, these considerations lend a substantial depth of prospective to the project. Our assessment process evaluates the ability for the lead scientist to participate in the project, the potentiality to attract non-dilutive capital, scientific feasibility and host-institution licensing options. A committee of advisors actively engaged in the development and success of each project will carefully select each newly scored, fully assessed proposal.
AV has developed a 48-point checklist for due diligence including the background science, the partnerships, the current marketplace, emerging scientific factors, the impact of the host institution, and a close look at the scientists themselves. AV is evolving its due diligence platform through conversations with AngelPlus, a due diligence service for early investors that includes a vast network of successful angel investors and their key contacts. For more mature projects, AV uses CSI Diagnostics’ Organization Optimizer.
Having studied the best practices in technology transfer from Stanford to Tel Aviv, we are proud to foster a culture of innovation; there are no defaults, standard practices or inherited recipes. Each step of the process is continuously reviewed for new possibilities, efficiency, and greater reach. A casual and collegiate environment, open to suggestions from all sides, is crucial to our formula for greater success. We are engaged in an exercise that undertakes significant risks, so we refuse to fall into the infamous failure patterns in recent business history.
The fund, accelerator and sponsorship system are designed to create a “closed loop” of innovation and licensing. As a result, business development never stops for Accelerated Ventures. A successful exit continues the development of a project, returns capital to the inventors and the fund, and gives us valuable experience and visibility. These goals can be achieved by;
- licensing the underlying technology to an operating partner (pharmaceutical company or manufacturer)
- getting the next round of investment in the project from a new source
- launching a company
- participating in a joint venture
- going public (rare but possible)
- selling the company back to the host institution or inventor
- sending the inventor “back to the drawing board” for grant funding and waiting for new results (not a failure – just a delay), or
- splitting the project across multiple exit types.